Patents Assigned to Shaman Pharmaceuticals, Inc.
-
Publication number: 20020055541Abstract: The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as a dietary supplement to mammals suffering from elevated triglyceride levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypotriglyceridemic agents.Type: ApplicationFiled: August 2, 2001Publication date: May 9, 2002Applicant: Shaman Pharmaceuticals, Inc.Inventors: Wayne D. Inman, David C. Hopp
-
Patent number: 5925647Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).Type: GrantFiled: October 20, 1997Date of Patent: July 20, 1999Assignee: Shaman Pharmaceuticals, Inc.Inventor: Donald E. Bierer
-
Patent number: 5917052Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: September 28, 1994Date of Patent: June 29, 1999Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Diana M. Fort
-
Patent number: 5837255Abstract: The use of extracts from Harungana or Vismia spp. or anthracenone compounds harunganin and vismin contained therein or isolated therefrom as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from H. madagascariensis. As hypoglycemic agents, the extracts or anthracenone compounds harunganin and vismin are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: December 10, 1996Date of Patent: November 17, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Wayne DeWald Inman, Jian Luo
-
Patent number: 5827898Abstract: This invention is directed to methods for treatment of non-insulin-dependent diabetes mellitus, for reducing blood glucose levels, or hyperglycemia. The methods entail administering to a mammal in need of such treatment a therapeutically effective amount of a composition whose active ingredient consists essentially of a compound of the following structure or a pharmaceutically acceptable salt thereof: ##STR1## In the compound R and R' are independently H or a C.sub.1 -C.sub.20 alkyl or C.sub.2 -C.sub.20 alkenyl group which may be substituted or unsubstituted. Alternatively, R and R' are such that together a cycloalkyl or cycloalkenyl ring is formed. In the chain linking the two phenolic derivatives each of (C(R).dbd.C(R')) or (C(R)(R')) are the same or different. A and A' are independently C.sub.2 -C.sub.20 acylamino, C.sub.2 -C.sub.20 acyloxy, C.sub.2 -C.sub.20 alkanoyl, C.sub.2 -C.sub.20 alkoxycarbonyl, C.sub.1 -C.sub.20 alkoxyl, C.sub.1 -C.sub.20 alkyl amino, C.sub.2 -C.sub.20 alkyl carboxyl, amino, C.sub.Type: GrantFiled: October 7, 1996Date of Patent: October 27, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Atul S. Khandwala, Jian Luo
-
Patent number: 5811568Abstract: This invention pertains to a synthetic process for obtaining a unique phosphocholine derivative which has been isolated from the leaves of the plant Irbachia alata, identified to be 1,22-bis?2-(trimethylammonium)ethylphosphatyl! docosane is disclosed. Also disclosed is a synthetic process for obtaining a novel class of mono- and bis(phosphocholine) derivatives which are useful as antiinfective agents. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus.Type: GrantFiled: April 28, 1994Date of Patent: September 22, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Jeffrey M. Dener, Thien V. Truong
-
Patent number: 5753790Abstract: The use of extracts from Cryptolepis sp. or quinodoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: June 6, 1995Date of Patent: May 19, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventor: Donald E. Bierer
-
Patent number: 5747527Abstract: Novel hypoglycemically active eremophilanolide sesquiterpenes which can be isolated from Psacalium spp., processes for obtaining the novel eremophilanolide sesquiterpenes and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. Further described is the use of epicacalone, cacalone, cacalol or dimaturin as hypoglycemic agents, for example, in the treatment of diabetes. In a preferred embodiment, the hypoglycemically active compounds are obtained from the roots of Psacalium decompositum. As agents for the treatment of diabetes, the hypoglycemically active compounds of the present inventions are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.Type: GrantFiled: June 6, 1995Date of Patent: May 5, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Wayne D. Inman, Steven Row King, Joseph L. Evans, Jian Luo
-
Patent number: 5741926Abstract: Aniline derivatives useful as antihyperglycemic agents, pharmaceutical compositions comprising the aniline derivatives and methods for their use are described. The aniline derivatives are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).Type: GrantFiled: February 12, 1997Date of Patent: April 21, 1998Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Larisa G. Dubenko
-
Patent number: 5691386Abstract: A novel hypoglycemically active triterpenoid compound isolated in purified, preferably substantially purified, form from Salacia spp., processes for obtaining the novel triterpenoid compound, compositions comprising the triterpenoid compound and methods for use a hypoglycemic agent, for example, in the treatment of diabetes, are described. In a preferred embodiment, the triterpenoid compound is obtained from Salacia prinoides. As an agent for the treatment of diabetes, the novel triterpenoid is useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.Type: GrantFiled: April 16, 1996Date of Patent: November 25, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Wayne D. Inman, Michael John Reed
-
Patent number: 5681829Abstract: Certain phosphocholine derivatives having substantial antifungal therapeutic activity are disclosed. The phosphocholine derivatives may be chemically synthesized, enzymatically prepared or extracted from the plant Irlbachia alata. The phosphocholine derivatives are useful in treating fungal infections including those which are dermatophytic, systemic, ophthalmic and vaginal.Type: GrantFiled: April 5, 1995Date of Patent: October 28, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Michael Tempesta, Shivanand D. Jolad, Steven King, Guohua Mao, Reimar C. Bruening, John E. Kuo, Thien V. Troung, Donald E. Bierer, Jeffrey M. Dener
-
Patent number: 5681958Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel crytolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).Type: GrantFiled: June 7, 1995Date of Patent: October 28, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventor: Donald E. Bierer
-
Patent number: 5674900Abstract: Novel terpenoid-type quinones which can be obtained from Pycnanthus spp., processes for obtaining the novel terpenoid-type quinones and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes are described. In a preferred embodiment, the novel terpenoid-type quinones are obtained from the leaves and stems of Pycnanthus angolensis. As agents for the treatment of diabetes, the novel terpenoid quinones are useful for treating insulin-dependent (type I) and/or non-insulin-dependent (type II) diabetes.Type: GrantFiled: August 1, 1995Date of Patent: October 7, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Rosa P. Ubillas, Jolad D. Shivanand, Christopher D. Mendez, Diana M. Fort, Joseph L. Evans, Jian Luo
-
Patent number: 5668168Abstract: This invention pertains to a novel group of 1,2-dithiin compounds useful as antiinfective agents, and a novel synthetic process to produce the same. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus.Type: GrantFiled: June 6, 1995Date of Patent: September 16, 1997Assignees: Shaman Pharmaceuticals, Inc., The Regents of the University of MichiganInventors: Thien V. Truong, Donald E. Bierer, Jeffrey M. Dener, Richard Hector, Michael S. Tempesta, Bernard Loev, Wu Yang, Masato Koreeda
-
Patent number: 5648354Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.Type: GrantFiled: February 28, 1995Date of Patent: July 15, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Jeffrey M. Dener, Joane Litvak, Larisa G. Dubenko
-
Patent number: 5628999Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: June 6, 1995Date of Patent: May 13, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Jian Luo, Diana M. Fort, Donald E. Bierer, Reimar C. Bruening, Steven R. King, Thomas J. Carlson
-
Patent number: 5629319Abstract: The use of extracts from Cryptolepis sp. or quindoline alkaloids such quindoline and cryptolepine contained therein as hypoglycemic agents, as well as methods for obtaining the hypoglycemic agents are described. According to a preferred embodiment, the extracts are derived from Cryptolepis sanguinolenta. As hypoglycemic agents, the extracts or quindoline alkaloids such as quindoline or cryptolepine are useful for treating insulin-dependent (type I) and non-insulin-dependent (type II) diabetes.Type: GrantFiled: June 6, 1995Date of Patent: May 13, 1997Assignee: Shaman Pharmaceuticals, Inc.Inventors: Jian Luo, Diana M. Fort, Donald E. Bierer, Reimar C. Bruening
-
Patent number: 5583235Abstract: The present invention provides an improved procedure for the preparation of 3,6-disubstituted-1,2-dithiin derivatives, especially unsymmetrical 1,2-dithiins. In addition, the process offers significant process, scaleup, and safety advantages over the previously reported synthetic processes. The compounds synthesized by this new process and described herein are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Trichophyton rubrum, Candida parapsilosis, Candida tropicalis, or Candida krusei.Type: GrantFiled: March 11, 1994Date of Patent: December 10, 1996Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Jeffrey M. Dener, Thien V. Truong
-
Patent number: 5580897Abstract: Novel 1,2-dithiin compounds useful as antifungal or anti-infective agents, as well as methods for their use as such, are described.Type: GrantFiled: February 28, 1995Date of Patent: December 3, 1996Assignee: Shaman Pharmaceuticals, Inc.Inventors: Donald E. Bierer, Patricia Peterli-Roth
-
Patent number: 5556875Abstract: This invention pertains to a novel group of 1,2-dithiin compounds useful as antiinfective agents, and a novel synthetic process to produce the same. The compounds are particularly effective in treating fungal infections, especially those caused by Candida albicans, Cryptococcus neoformans or Aspergillus fumigatus.Type: GrantFiled: August 24, 1995Date of Patent: September 17, 1996Assignees: Shaman Pharmaceuticals, Inc., The Regents of the University of MichiganInventors: Thien V. Truong, Donald E. Bierer, Jeffrey M. Dener, Richard Hector, Michael S. Tempesta, Bernard Loev, Wu Yang, Masato Koreeda